SCHEMBL17456008

SCHEMBL17456008

COc1ccc(CN2CCN(C(=O)c3cc(C)ccc3-c3ccncc3)CC2)cc1

nearest known ligand 0.78

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 10/20 0.78
▸ LSS P48449 1/20 0.66
▸ ALDH1A1 P00352 3/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ BCHE P06276 1/20 0.53
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ LMNA P02545 1/20 0.49
▸ HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455996 0.88 CYP46A1 (1.00) CYP46A1ALDH1A1KDM4EPOLBHTT
SCHEMBL17505980 0.87 LSS (0.70) CYP46A1LSSALDH1A1KDM4EBCHE
SCHEMBL25961329 0.79 KDM4E (0.65) CYP46A1LSSALDH1A1KDM4EPOLB
SCHEMBL17456047 0.78 LSS (0.53) CYP46A1LSSALDH1A1KDM4EBCHE
SCHEMBL17455930 0.75 LSS (0.57) CYP46A1LSSALDH1A1KDM4EBCHE
SCHEMBL17455981 0.75 CYP46A1 (0.74) CYP46A1ALDH1A1POLBCYP2C9TSHR
SCHEMBL14840775 0.75 CYP46A1 (0.72) CYP46A1ALDH1A1KDM4EHTT
SCHEMBL14841158 0.74 CYP46A1 (0.79) CYP46A1ALDH1A1KDM4EHTT
SCHEMBL17455928 0.73 CYP46A1 (1.00) CYP46A1
SCHEMBL14849038 0.73 CYP46A1 (1.00) CYP46A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CYP46A1 915/4885LSS 1343/4885ALDH1A1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback